Prevention of oncological diseases: Primary and secondary prevention

International Journal of Biological Markers

Volumn 27, Issue 4, 2012, Pages

  Chow, Louis W C ^a,b,c   Yip, Adrian Y S ^a   Ng, Elizabeth L Y ^a  

^a Organisation for Oncology and Translational Research   (Hong Kong)

^b UNIMED Medical Institute   (Hong Kong)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Oncological diseases; Primary prevention; Screening; Secondary prevention; Vaccination

Indexed keywords

ALPHA FETOPROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; CA 15-3 ANTIGEN; CA 27-29 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CEVARIX; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEPATITIS B VACCINE; LAPATINIB; MICRORNA; PROSTATE SPECIFIC ANTIGEN; TRASTUZUMAB; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER IMMUNIZATION; CANCER SCREENING; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; DRUG SAFETY; DRUG TOLERABILITY; GENE MUTATION; HUMAN; LIVER CELL CARCINOMA; NEOPLASM; OVARY CANCER; RISK FACTOR; UTERINE CERVIX CANCER;

CANCER VACCINES; CLINICAL TRIALS AS TOPIC; EARLY DETECTION OF CANCER; FEMALE; HEALTH BEHAVIOR; HUMANS; LIFE STYLE; MALE; NEOPLASMS; SECONDARY PREVENTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84872863860     PISSN: 03936155     EISSN: 17246008     Source Type: Journal    
DOI: 10.5301/JBM.2012.10370     Document Type: Article

References (56)

1. Stein CJ, Colditz GA. Modifiable risk factors for cancer. Br J Cancer 2004; 90: 299-303.
2. Southey MC, Ramus SJ, Dowty JG, et al. Morphological predictors of BRCA1 germline mutations in young women with breast cancer. Br J Cancer 2011; 104: 903-9.
3. World Health Organization: Hepatitis B. http://www.who.int/mediacentre/factsheets/fs204/en/ Accessed: 4 September 2012.
4. Tanaka M, Katayama F, Kato H, et al. Hepatitis B and C virus infection and hepatocellular carcinoma in China: a review of epidemiology and control measures. J Epidemiol 2011; 21: 401-16.
5. Williams JH, Phillips TD, Jolly PE, Stiles JK, Jolly CM, Aggarwal D. Human aflatoxicosis in developing countries: a review of toxicology, exposure, potential health consequences, and interventions. Am J Clin Nutr 2004; 80: 1106-22.
6. Yu J, Cleveland TE, Nierman WC, Bennett JW. Aspergillus flavus genomics: gateway to human and animal health, food safety, and crop resistance to diseases. Rev Iberoam Micol 2005; 22: 194-202.
7. Chanda A, Roze LV, Linz JE. A possible role for exocytosis in aflatoxin export in Aspergillus parasiticus. Eukaryot Cell 2010; 9: 1724-7.
8. Frisvad JC, Skouboe P, Samson RA. Taxonomic comparison of three different groups of aflatoxin producers and a new efficient producer of aflatoxin B1, sterigmatocystin and 3-O-methylsterigmatocystin, Aspergillus rambellii sp. nov. Syst Appl Microbiol 2005; 28: 442-53.
9. Peraica M, Radić B, Lucić A, Pavlović M. Toxic effects of mycotoxins in humans. Bull World Health Organ 1999; 77: 754-66.
10. McLean M, Dutton MF. Cellular interactions and metabolism of aflatoxin: an update. Pharmacol Ther 1995; 65: 163-92.
11. Eaton, DL, Groopman JD. The toxicology of aflatoxins. New York: Academic Press, 1994; 383-426.
12. Krogh P. Detection of fungi in stored grains and estimation of mycotoxins. In: Mathur SB, Jorgensen J, eds. Seed pathology. Copenhagen: Technical Centre for Agricultural Rural Cooperation, 1992; 149-57.
13. Prasad T. Detection of fungi in stored grains and estimation of mycotoxins. In: Mathur SB, Jorgensen J, eds. Seed pathology. Copenhagen: Technical Centre for Agricultural Rural Cooperation, 1992; 175-81.
14. Hutton DW, So SK, Brandeau ML. Cost-effectiveness of nationwide hepatitis B catch-up vaccination among children and adolescents in China. Hepatology 2010; 51: 405-14.
15. Centers for Disease Control and Prevention (CDC). Progress in hepatitis B prevention through universal infant vaccination - China, 1997-2006. MMWR Morb Mortal Wkly Rep 2007; 56: 441-5.
16. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008: Cancer incidence and mortality worldwide. International Agency for Research on Cancer; 2010. Available from: http://globocan.iarc.fr. Accessed June 2010.
17. Mah CL, Deber RB, Guttmann A, McGeer A, Krahn M. Another look at the human papillomavirus vaccine experience in Canada. Am J Public Health 2011; 101: 1850-7.
18. Stanley M. Pathology and epidemiology of HPV infection in females. Gynecol Oncol 2010; 117: S5-10.
19. Carter JR, Ding Z, Rose BR. HPV infection and cervical disease: a review. Aust N Z J Obstet Gynaecol 2011; 51: 103-8.
20. Palefsky JM, Giuliano AR, Goldstone S, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011; 365: 1576-85.
21. Chen Q, Xie LX, Qing ZR, et al. Epidemiologic characterization of human papillomavirus infection in rural Chaozhou, eastern Guangdong Province of China. PLoS One 2012; 7: e32149.
22. McCormack PL, Joura EA. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women. BioDrugs 2011; 25: 339-43.
23. Schmidt-Grimminger DC, Bell MC, Muller CJ, Maher DM, Chauhan SC, Buchwald DS. HPV infection among rural American Indian women and urban white women in South Dakota: an HPV prevalence study. BMC Infect Dis 2011; 11: 252.
24. Ragin CC, Wheeler VW, Wilson JB, et al. Distinct distribution of HPV types among cancer-free Afro-Caribbean women from Tobago. Biomarkers 2007; 12: 510-22.
25. Andall-Brereton GM, Hosein F, Salas RA, et al. Human papillomavirus genotypes and their prevalence in a cohort of women in Trinidad. Rev Panam Salud Publica 2011; 29: 220-6.
26. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
27. Li J, Kang LN, Qiao YL. Review of the cervical cancer disease burden in mainland China. Asian Pac J Cancer Prev 2011; 12: 1149-53.
28. Toi M, Ohashi Y, Seow A, et al. The Breast Cancer Working Group presentation was divided into three sections: the epidemiology, pathology and treatment of breast cancer. Jpn J Clin Oncol 2010; 40: i13-8.
29. Hortobágyi GN. A time for creative collaboration. Cancer 2008; 113: 2217-20.
30. Michaelson JS, Silverstein M, Sgroi D, et al. The effect of tumor size and lymph node status on breast carcinoma lethality. Cancer 2003; 98: 2133-43.
31. Bretthauer M. Colorectal cancer screening. J Intern Med 2011; 270: 87-98.
32. Dove-Edwin I, Sasieni P, Adams J, Thomas HJ. Prevention of colorectal cancer by colonoscopic surveillance in individuals with a family history of colorectal cancer: 16 year, prospective, follow-up study. BMJ 2005; 331: 1047.
33. Niv Y, Dickman R, Figer A, Abuksis G, Fraser G. Case-control study of screening colonoscopy in relatives of patients with colorectal cancer. Am J Gastroenterol 2003; 98: 486-9.
34. Sharp L, Tilson L, Whyte S, et al. Cost-effectiveness of population-based screening for colorectal cancer: a comparison of guaiac-based faecal occult blood testing, faecal immunochemical testing and flexible sigmoidoscopy. Br J Cancer 2012; 106: 805-16.
35. Nodora JN, Martz WD, Ashbeck EL, Jacobs ET, Thompson PA, Martínez ME. Primary care physician compliance with colorectal cancer screening guidelines. Cancer Causes Control 2011; 22: 1277-87.
36. Hoffman RM, Rhyne RL, Helitzer DL, et al. Barriers to colorectal cancer screening: physician and general population perspectives, New Mexico, 2006. Prev Chronic Dis 2011; 8: A35.
37. Arber N, Spicak J, Racz I, et al. Five-year analysis of the prevention of colorectal sporadic adenomatous polyps trial. Am J Gastroenterol 2011; 106: 1135-46.
38. Avivi D, Moshkowitz M, Detering E, Arber N. The role of low-dose aspirin in the prevention of colorectal cancer. Expert Opin Ther Targets 2012; 16: S51-62.
39. Sharkey RM, Goldenberg DM. Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. CA Cancer J Clin 2006; 56: 226-43.
40. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005; 23: 1147-57.
41. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72: 1117-30.
42. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007; 25: 1329-33.
43. Risch HA, McLaughlin JR, Cole DE, et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst 2006; 98: 1694-706.
44. Pal T, Permuth-Wey J, Betts JA, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 2005; 104: 2807-16.
45. Li H, Sekine M, Tung N, Avraham HK. Wild-type BRCA1, but not mutated BRCA1, regulates the expression of the nuclear form of beta-catenin. Mol Cancer Res 2010; 8: 407-20.
46. Woolf SH, Harris R. The harms of screening: new attention to an old concern. JAMA 2012; 307: 565-6.
47. Hayes DF, Bast RC, Desch CE, et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996; 88: 1456-66.
48. Kulasingam V, Diamandis EP. Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat Clin Pract Oncol 2008; 5: 588-99.
49. Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumorderived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 2008; 110: 13-21.
50. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006; 6: 259-69.
51. Lawrie CH, Gal S, Dunlop HM, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 2008; 141: 672-5.
52. Li L, Guo Z, Wang J, Mao Y, Gao Q. Serum miR-18a: A potential marker for hepatitis B virus-related hepatocellular carcinoma screening. Dig Dis Sci 2012; 57: 2910-6.
53. Mar-Aguilar F, Luna-Aguirre CM, Moreno-Rocha JC, et al. Differential expression of miR-21, miR-125b and miR-191 in breast cancer tissue. Asia Pac J Clin Oncol 2012. doi: 10.1111/j.1743-7563.2012.01548.x
54. Hennessey PT, Sanford T, Choudhary A, et al. Serum microRNA biomarkers for detection of non-small cell lung cancer. PLoS One 2012; 7: e32307.
55. Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer 2010; 127: 118-26.
56. Redova M, Poprach A, Nekvindova J, et al. Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J Transl Med 2012; 10: 55.